Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

1.070 +0.080 (+8.08%)

Streaming Delayed Price Updated: 2:56 PM EDT, May 12, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	164,440
Open	1.050
Bid (Size)	1.070 (200)
Ask (Size)	1.080 (300)
Prev. Close	0.9900
Today's Range	0.9900 - 1.070
52wk Range	0.9523 - 22.60
Shares Outstanding	38,262,586
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

May 11, 2026

Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global Crisis

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics CEO Issues Letter to Shareholders

May 05, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Performance

YTD	-77.7%	-77.7%
1 Month	-21.9%	-21.9%
3 Month	-78.7%	-78.7%
6 Month	-85.0%	-85.0%
1 Year	-93.9%	-93.9%

More News

FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring

May 04, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

May 04, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

April 30, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

April 30, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Compliant with All Nasdaq Listing Requirements

April 20, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

April 10, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Closing of $3 Million Public Offering

April 02, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Which stocks are moving before the opening bell on Wednesday? ↗

April 01, 2026

Via Chartmill

FibroBiologics Announces Pricing of $3 Million Public Offering

March 31, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Top movers in Tuesday's after hours session ↗

March 31, 2026

Via Chartmill

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

March 31, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 31, 2026

Via Chartmill

Which stocks are experiencing notable movement on Tuesday? ↗

March 31, 2026

Via Chartmill

The market is filled with gapping stocks in Tuesday's session. ↗

March 31, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

March 25, 2026

Via Chartmill

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement

March 25, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed

March 18, 2026

From USA News Group

Via GlobeNewswire

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

March 12, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

March 05, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

March 02, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics to Present at the BIO Investment & Growth Summit

February 26, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

February 24, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

February 23, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is FibroBiologics, Inc. - Common Stock publicly traded?

Yes, FibroBiologics, Inc. - Common Stock is publicly traded.

What exchange does FibroBiologics, Inc. - Common Stock trade on?

FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for FibroBiologics, Inc. - Common Stock?

The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market

What is the current price of FibroBiologics, Inc. - Common Stock?

The current price of FibroBiologics, Inc. - Common Stock is 1.070

When was FibroBiologics, Inc. - Common Stock last traded?

The last trade of FibroBiologics, Inc. - Common Stock was at 05/12/26 02:56 PM ET

What is the market capitalization of FibroBiologics, Inc. - Common Stock?

The market capitalization of FibroBiologics, Inc. - Common Stock is 40.94M

How many shares of FibroBiologics, Inc. - Common Stock are outstanding?

FibroBiologics, Inc. - Common Stock has 41M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.